Phase 2 Kidney Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You must be at least 18 years old at the time of signing the consent form.
• You must have a type of kidney cancer called clear cell renal cell carcinoma (or a related type that includes clear cell features) that cannot be surgically removed or has spread, and has gotten worse despite previous treatment.
• You must have already received at least one immunotherapy treatment (targeting PD-1 or PD-L1) and at least one targeted therapy for blood vessel growth (VEGF pathway), or have been unable to tolerate or use these standard treatments.
• You must have at least one area of cancer that can be measured on a scan, using standard measurement guidelines.
• You must be able to provide a stored tumor tissue sample or agree to have a new biopsy taken, so the tumor can be tested for specific proteins (CD70 and/or CAIX); your tumor must test positive for at least one of these proteins to be eligible.
• You must be reasonably active and able to care for yourself (confirmed by a standard doctor's assessment scale called ECOG, scored 0 or 1).
• Your blood counts, liver, heart, lungs, and kidneys must be working well enough, as defined by the trial's specific measurements.
• You must be expected to live for at least 12 weeks.
• If you could become pregnant, you must have a negative pregnancy test and agree to use highly effective contraception during the periods specified by the trial.
• If you have had cancer spread to the brain in the past, it may still be allowed if it is stable and you have not needed increasing steroid doses for at least 14 days before a specific treatment step called lymphodepletion.

Who may not be able to join:

• You may not join if you have active, untreated, or symptomatic cancer spread to the brain or the lining around the brain, or if you have seizures that are not under control.
• You may not join if you have recently received a type of gene-modified cell therapy (such as CAR-T cell therapy or similar treatments) within the timeframe set by the trial.
• You may not join if you have previously had a bone marrow transplant from a donor or an organ transplant and still need significant immune-suppressing medication as a result.
• You may not join if you have an active autoimmune disease that requires immune-suppressing medication (low-dose replacement therapy may be allowed — confirm with trial site).
• You may not join if you have an active, uncontrolled infection, including uncontrolled hepatitis B, hepatitis C, HIV, tuberculosis, or a serious blood infection (sepsis).
• You may not join if you have significant liver or bile duct disease, such as active bile duct inflammation, bile duct blockage, moderate-to-severe liver scarring (cirrhosis), or a history of a specific type of liver vessel damage (confirm with trial site).
• You may not join if you have serious heart problems, such as unstable chest pain, a recent heart attack, an uncontrolled irregular heartbeat, or significant heart failure.
• You may not join if you have been taking steroid medications (such as prednisone) at a dose higher than 10 mg per day within 7 days before the lymphodepletion treatment step, unless it is for a necessary replacement dose.
• You may not join if you are currently pregnant or breastfeeding.
• You may not join if you have another active cancer that requires systemic treatment, with some limited exceptions defined by the trial.
• You may not join if you have a known allergy or serious reaction to fludarabine, cyclophosphamide, or key ingredients in the study treatment.

Important: Always verify eligibility with the trial site directly before applying.